Paper Details

  1. Home
  2. Paper Details

[Darunavir in treatment-naïve patients. The ARTEMIS study].

Author: EstradaVicente, FusterMónica

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The ARTEMIS study compared the effectiveness of darunavir/ritonavir and lopinavir/ritonavir for treating HIV in people who had never taken HIV medications before. Both medications were effective, but darunavir/ritonavir was more effective in patients with higher levels of HIV in their blood. Darunavir/ritonavir also had fewer side effects, particularly digestive problems and changes in lipid levels.
Paper Details　
Original Abstract of the Article :
The ARTEMIS study compared the efficacy of darunavir/ritonavir at once-daily doses of 800/100 mg versus once- or twice-daily doses of lopinavir/ritonavir, together with 300 mg of tenofovir and 200 mg of emtricitabine, both in once-daily doses, in treatment-naive patients. The results at 48 weeks sho...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0213-005x(08)76548-0

データ提供：米国国立医学図書館（NLM）

Darunavir: A Promising Treatment Option for HIV-1 Infection

HIV-1 infection, a complex and challenging condition, requires effective treatment regimens to manage the virus and improve patient health. This study, the ARTEMIS study, compares the efficacy of darunavir/ritonavir with lopinavir/ritonavir in treatment-naïve patients with HIV-1 infection. Both drug combinations were evaluated in conjunction with tenofovir and emtricitabine, standard components of antiretroviral therapy. The study aimed to assess the effectiveness of darunavir/ritonavir in suppressing viral load and increasing CD4 cell count in patients newly diagnosed with HIV-1.

Darunavir Shows Promise in HIV-1 Treatment

The findings suggest that darunavir/ritonavir is non-inferior to lopinavir/ritonavir in suppressing viral load and increasing CD4 cell count. The study also indicates that darunavir/ritonavir may be superior to lopinavir/ritonavir in patients with high viral loads. Additionally, darunavir/ritonavir was associated with a lower incidence of side effects, particularly gastrointestinal and lipidic adverse effects. These findings suggest that darunavir/ritonavir may be a valuable treatment option for HIV-1 infection, offering a more effective and tolerable alternative to existing regimens.

Navigating the Desert of HIV-1 Treatment

This research, like a camel navigating a treacherous desert, highlights the ongoing efforts to develop effective treatments for HIV-1 infection. The emergence of new drugs like darunavir, like finding a hidden oasis, offers hope for patients facing this complex and challenging condition. By continuing to explore new treatment options, we can create a brighter future for individuals living with HIV-1.

Dr.Camel's Conclusion

HIV-1 infection, like a desert mirage, can be both alluring and daunting. This study, like a compass guiding travelers through a vast and unknown territory, sheds light on the potential of darunavir as a promising treatment option. The discovery of new and effective therapies, like finding a source of water in a parched desert, offers hope and resilience for those living with HIV-1.

Date :
  1. Date Completed 2009-05-05
  2. Date Revised 2019-09-23
Further Info :

Pubmed ID

19195454

DOI: Digital Object Identifier

10.1016/s0213-005x(08)76548-0

SNS
PICO Info
in preparation
Languages

Spanish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.